Business Context and Reporting Period
This Form 8-K is a current report filed by Centene Corporation on August 12, 2026, with events reported through August 17, 2026. The filing primarily addresses significant executive leadership changes within the finance function and a reaffirmation of the company's full-year financial guidance.
Key Financial Metrics and Compensation
The filing does not report operational financial metrics such as revenue, profit, cash flow, or debt levels for the current period. However, it discloses specific compensation terms for the incoming Chief Financial Officer:
- Base Salary: $1,100,000 annually.
- Target Cash Bonus: 150% of base salary (up to 200% potential).
- Long-Term Equity Incentives (2027): Target value of $5,250,000.
- Sign-on Compensation: $10,000,000 in restricted stock units (vesting over 3 years) and a $2,000,000 cash bonus.
Material Changes
The filing details a planned transition of the Chief Financial Officer (CFO) role:
- Departure: Andrew Asher, current CFO, intends to retire effective December 31, 2026. He will serve as a Strategic Advisor through the end of 2027.
- Succession: Christopher Neczypor has been identified as the successor. He will begin as Executive Vice President on or about September 1, 2026, and assume the CFO role effective January 1, 2027.
- Guidance Reaffirmation: On August 17, 2026, the company reaffirmed its full-year 2026 adjusted diluted earnings per share (EPS) guidance of greater than $4.80, consistent with the July 28, 2026, second-quarter earnings release.
- Regulatory and Political Risks: Potential changes in federal or state laws, funding for government-sponsored healthcare programs, and the impact of U.S. presidential administrations or Congress.
- Operational Risks: Fluctuations in medical costs, inflation, provider behaviors, and the ability to maintain CMS Star ratings.
- Transition Risks: Risks associated with the timing and terms of the CFO transition and the integration of new leadership.
- Market Risks: Competition, contract reprocurements, and the ability to design competitive and actuarially sound products.
- Verify the exact start date of Christopher Neczypor's role as Executive Vice President (expected September 1, 2026) and CFO (expected January 1, 2027).
- Confirm the vesting schedule and forfeiture conditions for the $10 million restricted stock unit grant and $2 million cash sign-on bonus.
- Review the full text of the Employment Agreement (to be filed as an exhibit in a future periodic report) for complete terms.
- Monitor subsequent earnings reports to ensure the reaffirmed adjusted diluted EPS guidance of >$4.80 is met.
- Assess the impact of the CFO transition on the company's enterprise optimization initiatives and strategic direction.
Outlook, Risks, and Contingencies
Management has reaffirmed its 2026 financial outlook despite the leadership transition. The filing includes extensive forward-looking statements and risk factors, including: